A detailed history of Pathstone Family Office, LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Pathstone Family Office, LLC holds 181,425 shares of BMY stock, worth $10.7 Million. This represents 0.07% of its overall portfolio holdings.

Number of Shares
181,425
Previous 51,749 250.59%
Holding current value
$10.7 Million
Previous $3.31 Million 218.19%
% of portfolio
0.07%
Previous 0.05%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 08, 2023

BUY
$57.89 - $64.73 $7.51 Million - $8.39 Million
129,676 Added 250.59%
181,425 $10.5 Million
Q2 2023

Jan 12, 2024

SELL
$63.71 - $70.74 $8.08 Million - $8.97 Million
-126,810 Reduced 69.9%
54,615 $3.49 Million
Q2 2023

Aug 14, 2023

BUY
$63.71 - $70.74 $289,179 - $321,088
4,539 Added 9.61%
51,749 $3.31 Million
Q1 2023

May 15, 2023

SELL
$65.71 - $74.53 $2.55 Million - $2.9 Million
-38,880 Reduced 45.16%
47,210 $3.27 Million
Q4 2022

Oct 23, 2023

BUY
$68.48 - $81.09 $3.11 Million - $3.69 Million
45,469 Added 111.93%
86,090 $6.19 Million
Q4 2022

Feb 13, 2023

BUY
$68.48 - $81.09 $742,528 - $879,258
10,843 Added 14.41%
86,090 $6.19 Million
Q3 2022

Oct 23, 2023

BUY
$0.13 - $76.84 $2,538 - $1.5 Million
19,524 Added 92.54%
40,621 $2.89 Million
Q3 2022

Nov 14, 2022

BUY
$0.13 - $76.84 $2,352 - $1.39 Million
18,098 Added 31.67%
75,247 $5.46 Million
Q2 2022

Oct 23, 2023

SELL
$72.62 - $79.98 $2.23 Million - $2.45 Million
-30,652 Reduced 59.23%
21,097 $1.62 Million
Q2 2022

Aug 15, 2022

BUY
$72.62 - $79.98 $3.65 Million - $4.01 Million
50,194 Added 721.7%
57,149 $4.4 Million
Q1 2022

May 16, 2022

BUY
$61.48 - $73.72 $75,128 - $90,085
1,222 Added 21.32%
6,955 $624,000
Q4 2021

Feb 14, 2022

SELL
$53.63 - $62.52 $143,406 - $167,178
-2,674 Reduced 31.81%
5,733 $357,000
Q3 2021

Nov 16, 2021

BUY
$59.17 - $69.31 $75,382 - $88,300
1,274 Added 17.86%
8,407 $499,000
Q2 2021

Aug 31, 2021

SELL
$61.91 - $67.42 $55,285 - $60,206
-893 Reduced 11.13%
7,133 $477,000
Q1 2021

May 14, 2021

BUY
$59.34 - $66.74 $111,381 - $125,270
1,877 Added 30.53%
8,026 $508,000
Q4 2020

Feb 16, 2021

BUY
$57.74 - $65.43 $213,638 - $242,091
3,700 Added 151.08%
6,149 $381,000
Q3 2020

Nov 12, 2020

BUY
$57.43 - $63.64 $31,529 - $34,938
549 Added 28.89%
2,449 $147,000
Q2 2020

Aug 14, 2020

BUY
$54.82 - $64.09 $10,964 - $12,818
200 Added 11.76%
1,900 $112,000
Q1 2020

Jun 11, 2020

BUY
$46.4 - $67.43 $78,880 - $114,631
1,700 New
1,700 $95,000
Q1 2020

May 07, 2020

SELL
$46.4 - $67.43 $125,280 - $182,061
-2,700 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$49.21 - $64.19 $32,970 - $43,007
670 Added 33.0%
2,700 $1.73 Million
Q3 2019

Nov 13, 2019

SELL
$42.77 - $50.71 $28,655 - $33,975
-670 Reduced 24.81%
2,030 $104,000
Q2 2019

Aug 14, 2019

BUY
$44.62 - $49.34 $71,392 - $78,944
1,600 Added 145.45%
2,700 $122,000
Q1 2019

May 14, 2019

BUY
$45.12 - $53.8 $16,739 - $19,959
371 Added 50.89%
1,100 $52,000
Q4 2018

Feb 14, 2019

BUY
$48.76 - $63.23 $1,414 - $1,833
29 Added 4.14%
729 $38,000
Q3 2017

Nov 14, 2017

SELL
$55.23 - $63.74 $386 - $446
-7 Reduced 0.99%
700 $45,000
Q2 2017

Aug 16, 2017

BUY
N/A
707
707 $39,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $125B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Pathstone Family Office, LLC Portfolio

Follow Pathstone Family Office, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pathstone Family Office, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pathstone Family Office, LLC with notifications on news.